27 June 2016 - On 31 May 2016, BioMarin officially notified the CHMP that it wishes to withdraw its application for a marketing authorisation for Kyndrisa (drisapersen) for the treatment of Duchenne muscular dystrophy.
Kyndrisa was expected to be used for the treatment of Duchenne muscular dystrophy in patients aged 5 years and older who are able to walk and whose disease is due to certain genetic mutations (defects) that can be treated with ‘exon 51 skipping technology’.